PanGenomic Health, Inc. Class A (TSE:NARA)
:NARA
Want to see TSE:NARA full AI Analyst Report?
NARA Stock Chart & Stats
C$0.51
C$0.04(33.33%)
At close: 4:00 PM EST
C$0.51
C$0.04(33.33%)
Day’s Range― - ―
52-Week RangeC$0.29 - C$2.57
Previous CloseN/A
Volume0.00
Average Volume (3M)110.39K
Market Cap
C$4.49M
Enterprise ValueC$4.94M
Total Cash (Recent Filing)C$40.85K
Total Debt (Recent Filing)C$482.87K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding14,046,870
10 Day Avg. Volume77,322
30 Day Avg. Volume110,395
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-3.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Lean HeadcountA very small workforce materially lowers fixed operating costs and increases organizational agility. Over a multi-month horizon this reduces required cash runway and allows management to reallocate limited capital toward product development or regulatory milestones rather than payroll.
Modest Absolute DebtRelatively limited absolute debt reduces near-term interest and refinancing pressure compared with higher-leverage peers. With low nominal borrowings the company has more flexibility to secure incremental financing or restructure obligations while it pursues revenue generation.
Industry Secular TailwindsOperating in healthcare information services exposes the company to durable demand for digital health data, analytics, and compliance solutions. Structural industry needs create potential for recurring revenue and long-term adoption if the company achieves product-market fit and regulatory compliance.
Bears Say
No Reported RevenueAbsence of revenue is a critical structural weakness: without product sales or recurring contracts the company cannot self-fund operations. Persisting in this state forces continual external financing, increases dilution risk, and prevents proof of commercial viability over the medium term.
Sustained Cash BurnMaterial and accelerating negative operating cash flow indicates ongoing cash consumption and rising funding needs. Over several months this erodes liquidity, elevates fundraising urgency, and constrains investment in product development, commercial scaling, or regulatory milestones.
Negative Shareholders' EquityAccumulated losses producing negative equity weaken solvency and creditor confidence. Structurally this limits access to low-cost capital, increases dependence on dilutive financing or expensive debt, and heightens the risk of restructuring if operating performance does not improve.
PanGenomic Health, Inc. Class A News
NARA FAQ
What was PanGenomic Health, Inc. Class A’s price range in the past 12 months?
PanGenomic Health, Inc. Class A lowest stock price was C$0.29 and its highest was C$2.57 in the past 12 months.
What is PanGenomic Health, Inc. Class A’s market cap?
PanGenomic Health, Inc. Class A’s market cap is C$4.49M.
When is PanGenomic Health, Inc. Class A’s upcoming earnings report date?
PanGenomic Health, Inc. Class A’s upcoming earnings report date is Aug 27, 2026 which is in 70 days.
How were PanGenomic Health, Inc. Class A’s earnings last quarter?
Currently, no data Available
Is PanGenomic Health, Inc. Class A overvalued?
According to Wall Street analysts PanGenomic Health, Inc. Class A’s price is currently Overvalued.
Does PanGenomic Health, Inc. Class A pay dividends?
PanGenomic Health, Inc. Class A does not currently pay dividends.
What is PanGenomic Health, Inc. Class A’s EPS estimate?
PanGenomic Health, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PanGenomic Health, Inc. Class A have?
PanGenomic Health, Inc. Class A has 14,046,870 shares outstanding.
What happened to PanGenomic Health, Inc. Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PanGenomic Health, Inc. Class A?
Currently, no hedge funds are holding shares in TSE:NARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PanGenomic Health, Inc. Class A
Pangenomic Health Inc., a precision health enterprise, develops a digital self-care platform designed to deliver personalized, scientifically-backed information on natural treatments for mental well-being. This platform includes the Nara App, a mobile application for consumers that offers a knowledge base tailored to individual user profiles. Additionally, the company provides the PlantGx Platform, a digital therapeutics solution for clinics, enabling healthcare professionals to access patient health data (with patient authorization) originating from the Nara App and facilitating patient referrals. The firm, established in 2015, previously operated as Zetta Capital Corp. before rebranding to PanGenomic Health Inc. in December 2021. Its headquarters are located in Vancouver, Canada.
Technical Analysis
Diagnos
―
nDatalyze Corp
―
Rocket Doctor AI
―
UniDoc Health Corp
―
DiagnaMed Holdings Corp.
―
Options Prices
Currently, No data available
---